Healthcare company Baxter International (NYSE: BAX) will be reporting earnings this Thursday before market open. Here’s what investors should know.
Baxter missed analysts’ revenue expectations by 1.4% last quarter, reporting revenues of $2.84 billion, up 5% year on year. It was a softer quarter for the company, with a significant miss of analysts’ full-year EPS guidance estimates and revenue guidance for next quarter missing analysts’ expectations significantly.
Is Baxter a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, analysts are expecting Baxter’s revenue to grow 2.2% year on year to $2.81 billion, improving from its flat revenue in the same quarter last year. Adjusted earnings are expected to come in at $0.54 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Baxter has missed Wall Street’s revenue estimates six times over the last two years.
Looking at Baxter’s peers in the medical devices & supplies - diversified segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Neogen’s revenues decreased 2.8% year on year, beating analysts’ expectations by 7.2%, and Stryker reported revenues up 11.4%, topping estimates by 0.8%. Neogen traded up 30.4% following the results while Stryker was also up 4.3%.
Read our full analysis of Neogen’s results here and Stryker’s results here.
Debates over possible tariffs and corporate tax adjustments have raised questions about economic stability in 2025. While some of the medical devices & supplies - diversified stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.7% on average over the last month. Baxter is up 8.3% during the same time and is heading into earnings with an average analyst price target of $22.90 (compared to the current share price of $21.82).
Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
